Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 26.99 Billion KRW | 12.13% |
| 2022 | 24.07 Billion KRW | 9.33% |
| 2021 | 22.02 Billion KRW | 27.01% |
| 2020 | 17.33 Billion KRW | -1.74% |
| 2019 | 17.64 Billion KRW | 1.1% |
| 2018 | 17.45 Billion KRW | 1.44% |
| 2017 | 17.2 Billion KRW | -11.48% |
| 2016 | 19.43 Billion KRW | 4.75% |
| 2015 | 18.55 Billion KRW | -4.15% |
| 2014 | 19.35 Billion KRW | -7.69% |
| 2013 | 20.97 Billion KRW | -12.98% |
| 2012 | 24.09 Billion KRW | 45.57% |
| 2011 | 16.55 Billion KRW | 18.03% |
| 2010 | 14.02 Billion KRW | -12.42% |
| 2009 | 16.01 Billion KRW | 13.35% |
| 2008 | 14.12 Billion KRW | -17.32% |
| 2007 | 17.08 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 34.62 Billion KRW | 28.27% |
| 2024 Q3 | 29.17 Billion KRW | -16.24% |
| 2024 Q2 | 34.83 Billion KRW | 0.58% |
| 2023 Q2 | 30.99 Billion KRW | 15.05% |
| 2023 Q1 | 26.94 Billion KRW | 11.91% |
| 2023 FY | 26.99 Billion KRW | 12.13% |
| 2023 Q4 | 26.99 Billion KRW | -12.32% |
| 2023 Q3 | 30.79 Billion KRW | -0.66% |
| 2022 Q2 | 26.76 Billion KRW | 25.84% |
| 2022 Q3 | 21.95 Billion KRW | -17.96% |
| 2022 FY | 24.07 Billion KRW | 9.33% |
| 2022 Q4 | 24.07 Billion KRW | 9.67% |
| 2022 Q1 | 21.26 Billion KRW | -3.43% |
| 2021 Q2 | 18.42 Billion KRW | -5.1% |
| 2021 Q3 | 18.2 Billion KRW | -1.19% |
| 2021 Q4 | 22.02 Billion KRW | 20.99% |
| 2021 FY | 22.02 Billion KRW | 27.01% |
| 2021 Q1 | 19.41 Billion KRW | 11.95% |
| 2020 Q4 | 17.33 Billion KRW | -9.62% |
| 2020 FY | 17.33 Billion KRW | -1.74% |
| 2020 Q3 | 19.18 Billion KRW | 6.92% |
| 2020 Q2 | 17.94 Billion KRW | -1.26% |
| 2020 Q1 | 18.17 Billion KRW | 2.98% |
| 2019 Q3 | 18.89 Billion KRW | -0.11% |
| 2019 Q1 | 17.21 Billion KRW | -1.34% |
| 2019 Q2 | 18.91 Billion KRW | 9.83% |
| 2019 Q4 | 17.64 Billion KRW | -6.59% |
| 2019 FY | 17.64 Billion KRW | 1.1% |
| 2018 Q1 | 17.61 Billion KRW | 2.35% |
| 2018 FY | 17.45 Billion KRW | 1.44% |
| 2018 Q4 | 17.45 Billion KRW | 3.79% |
| 2018 Q3 | 16.81 Billion KRW | -6.5% |
| 2018 Q2 | 17.98 Billion KRW | 2.12% |
| 2017 Q2 | 20.63 Billion KRW | 3.98% |
| 2017 FY | 17.2 Billion KRW | -11.48% |
| 2017 Q4 | 17.2 Billion KRW | -11.86% |
| 2017 Q3 | 19.52 Billion KRW | -5.39% |
| 2017 Q1 | 19.84 Billion KRW | 2.09% |
| 2016 Q1 | 21.28 Billion KRW | 14.7% |
| 2016 FY | 19.43 Billion KRW | 4.75% |
| 2016 Q3 | 19.86 Billion KRW | -1.16% |
| 2016 Q4 | 19.43 Billion KRW | -2.14% |
| 2016 Q2 | 20.09 Billion KRW | -5.58% |
| 2015 Q3 | 20.43 Billion KRW | -5.35% |
| 2015 Q2 | 21.58 Billion KRW | -7.31% |
| 2015 Q1 | 23.29 Billion KRW | 20.32% |
| 2015 FY | 18.55 Billion KRW | -4.15% |
| 2015 Q4 | 18.55 Billion KRW | -9.2% |
| 2014 FY | 19.35 Billion KRW | -7.69% |
| 2014 Q4 | 19.35 Billion KRW | 4.06% |
| 2014 Q3 | 18.6 Billion KRW | 3.08% |
| 2014 Q1 | 19.48 Billion KRW | -7.11% |
| 2014 Q2 | 18.04 Billion KRW | -7.36% |
| 2013 Q3 | 22.52 Billion KRW | 5.01% |
| 2013 FY | 20.97 Billion KRW | -12.98% |
| 2013 Q4 | 20.97 Billion KRW | -6.91% |
| 2013 Q1 | 22.37 Billion KRW | -7.17% |
| 2013 Q2 | 21.45 Billion KRW | -4.11% |
| 2012 Q4 | 24.09 Billion KRW | 0.0% |
| 2012 Q1 | 15.59 Billion KRW | -5.82% |
| 2012 FY | 24.09 Billion KRW | 45.57% |
| 2011 FY | 16.55 Billion KRW | 18.03% |
| 2011 Q4 | 16.55 Billion KRW | -8.36% |
| 2011 Q3 | 18.06 Billion KRW | 6.49% |
| 2011 Q2 | 16.96 Billion KRW | 7.71% |
| 2011 Q1 | 15.74 Billion KRW | 12.29% |
| 2010 Q4 | 14.02 Billion KRW | 3.59% |
| 2010 Q1 | 17.39 Billion KRW | 8.62% |
| 2010 Q3 | 13.53 Billion KRW | -8.45% |
| 2010 FY | 14.02 Billion KRW | -12.42% |
| 2010 Q2 | 14.78 Billion KRW | -14.98% |
| 2009 Q2 | 11.22 Billion KRW | -29.75% |
| 2009 Q4 | 16.01 Billion KRW | 35.8% |
| 2009 Q3 | 11.79 Billion KRW | 5.1% |
| 2009 Q1 | 15.97 Billion KRW | 13.06% |
| 2009 FY | 16.01 Billion KRW | 13.35% |
| 2008 Q2 | 18.55 Billion KRW | -0.09% |
| 2008 Q3 | 17.78 Billion KRW | -4.15% |
| 2008 Q1 | 18.56 Billion KRW | 8.66% |
| 2008 FY | 14.12 Billion KRW | -17.32% |
| 2008 Q4 | 14.12 Billion KRW | -20.55% |
| 2007 Q2 | 15.79 Billion KRW | -16.06% |
| 2007 Q3 | 17.15 Billion KRW | 8.61% |
| 2007 Q1 | 18.82 Billion KRW | 0.0% |
| 2007 FY | 17.08 Billion KRW | 0.0% |
| 2007 Q4 | 17.08 Billion KRW | -0.41% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 38.852% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 77.092% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 70.386% |
| HANDOK Inc. | 94.46 Billion KRW | 71.42% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -27.091% |
| Yuhan Corporation | 284.75 Billion KRW | 90.519% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 76.789% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -66.053% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 90.652% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | 16.632% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 56.261% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -38.614% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | 10.84% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 44.158% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 38.852% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | 13.581% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 23.25% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 43.904% |
| JW Holdings Corporation | 147.58 Billion KRW | 81.707% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 68.096% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 89.673% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 74.552% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 49.933% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | 16.958% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 75.405% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 38.852% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 85.688% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 88.823% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 74.552% |
| Yuhan Corporation | 284.75 Billion KRW | 90.519% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 78.45% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 56.445% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 89.61% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 74.552% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 66.084% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 45.061% |
| CKD Bio Corp. | 69.08 Billion KRW | 60.919% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 74.307% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 61.812% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 50.057% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 49.933% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 86.138% |
| Boryung Corporation | 189.8 Billion KRW | 85.776% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 52.495% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 56.261% |
| JW Lifescience Corporation | 23.39 Billion KRW | -15.383% |